Clinical trial NCT01125241: A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression
Official title: A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression: a Muli-center, Randomized, Double-blinded, Placebo-controlled Superiority Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Epilepsy
Depression
Keywords: wuling capsule
epilepsy
depression
superiority clinical research
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
Collaborators: name: Shanghai Wu Mengchao Medical Foundation
name: Shanghai Ankang Pharmaceutical Co.,LTD
First posted: 2010-05-18
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to determine the effects of add-on therapy of wuling capsule on depressive symptoms in patients with comorbidity of epilepsy and depression, to evaluate its influences on the frequency and severity of seizures, and to observe its effects on patients' sleeping condition, quality of life.

Detailed description: The phenomenon of epileptic patients who have psychiatric disorders is very common, of which the prevalence of depression is the highest and depression is also an independent risk factor affecting epileptic patients' quality of life. Due to some social factors, non-typical clinical symptoms and limited therapeutic methods(tricyclic antidepressants, lithium chloride and 5-serotonin uptake inhibitors may all have risks of lowing threshold of seizures), epileptic patients with depression are usually not be recognized and treated properly. Wuling capsule has been used in therapy of insomnia, nervous breakdowns and a previous small sample clinical trial revealed that it could improve mood disorders of epileptic patients and hadn't affected severity of seizures (not published). Therefore a multi-center, randomized, double-blinded and placebo-controlled superiority clinical trial will be carried out to determine the effects of add-on therapy of wuling capsule on depressive symptoms in patients with epilepsy, to evaluate its influences on the frequency and severity of seizures, and to observe its effects on patients' sleeping condition, quality of life.

Eligibility criteria: Inclusion Criteria:

Subjects for this study will meet the following criteria:

1. Age greater than or equal to 18 years.
2. Must be in accordance with the diagnostic criteria of epilepsy and have taken antiepileptic drugs regularly at least for 6 months, which will not be changed recently. The duration to the latest seizure must be longer than 24 hours.
3. Score of a 17 item Hamilton Depression is greater than or equal to 17 and depressive symptoms have lasted for at least 2 weeks.
4. Haven't taken any anti-anxiety, anti-depressant and anti-psychotic drugs in recent 2 weeks.
5. Must sign the informed consent form.

Exclusion Criteria:

1. Now accepting or have accepted other drugs clinical trial in the last month.
2. History of serious psychiatric illness other than depression.
3. Having suicide ideas or suicide behaviors.
4. Progressive illness of central nervous system, such as degenerative disease or tumor.
5. History of serious cardiac or pulmonary disease, hepatic and renal dysfunction, and malignant tumors.
6. The value of ALT or AST is higher than 1.5 times normal range, or the number of white blood cells is less than 2500/ul, or the number of neutrophil granulocyte is less than 1000/ul.
7. During pregnant or lactation period.
8. The person who is disabled or mentally disabled.

Primary outcomes:
measure: symptoms of depression using the 17-item Hamilton Depression Rating Scale (HDRS)
timeFrame: 3 months
Secondary outcomes:
measure: the frequency of seizures using diary
timeFrame: 3 months
measure: the severity of seizures using the National Hospital Seizure Severity Scale(NHS3)
timeFrame: 3 months
measure: the sleeping condition using Pittsburgh Sleep Quality Index (PSQI)
timeFrame: 3 months
measure: the quality of life using Quality of Life in Epilepsy (QOLIE-31)
timeFrame: 3 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital, Beijing, China
state: Beijing
city: Guangzhou
country: China
facility: the Second Affiliated Hospital of Guangzhou Medical College, Guangzhou, China
state: Guangdong
city: Shanghai
country: China
facility: Shanghai Fifth People's Hospital
state: Shanghai
city: Shanghai
country: China
facility: Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China
state: Shanghai
city: Shanghai
country: China
facility: Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
state: Shanghai
city: Shanghai
country: China
facility: Department of Neurology, Renji Hospital, Shanghai Jiaotong University, Shanghai, China
state: Shanghai
city: Shanghai
country: China
facility: the Sixth People's Hospital of Shanghai Jiaotong University，Shanghai,China
state: Shanghai
city: Hangzhou
country: China
facility: Department of Neurology, Second Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
city: Guangzhou
country: China
facility: the First Municipal Hospital of Guangzhou
Study officials:
affiliation: Fudan University
name: Wang Xin, MD
role: PRINCIPAL_INVESTIGATOR
References: